Natixis Advisors
PTCT icon

Natixis Advisors’s PTC Therapeutics PTCT Stock Holding History

Natixis Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.07M Buy
+13,181
New +$952K ﹤0.01% 1457
2026
Q1 		– Sell
-11,456
Closed -$870K – 1737
2025
Q4 		$870K Sell
11,456
-1,294
-10% -$94K ﹤0.01% 1304
2025
Q3 		$782K Buy
+12,750
New +$664K ﹤0.01% 1390
2025
Q2 		– Sell
-15,220
Closed -$776K – 1681
2025
Q1 		$776K Buy
15,220
+3,160
+26% +$158K ﹤0.01% 1347
2024
Q4 		$544K Buy
+12,060
New +$516K ﹤0.01% 1452

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Natixis Advisors's PTCT Position: Q2 2026 in Review

Natixis Advisors opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 13,181 shares worth $1.07M. The stake represents ﹤0.01% of the portfolio and ranks #1457 among its holdings. This is a return to the name: Natixis Advisors previously reported a position in PTCT as recently as Q4 2025.

Natixis Advisors first reported a position in PTCT in Q4 2024 and has held it in 5 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Natixis Advisors held 13,181 shares of PTC Therapeutics worth $1.07M as of Q2 2026.
  • PTC Therapeutics was a new Natixis Advisors position in Q2 2026.
  • PTC Therapeutics made up ﹤0.01% of Natixis Advisors's portfolio in Q2 2026, its #1457 holding.
  • Natixis Advisors first reported a position in PTC Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.